Abstract

FORMULATION AND EVALUATION OF CHITOSAN NANOPARTICLE BASED IN-SITU NASAL GEL FOR PARKINSON’S DISEASE

Kiran A. Tengse*, Dr. Jasmine G. Avari and Pankaj Dhapke

Abstract

Parkinson’s disease is chronic progressive neurodegenerative disease. As the disease affects the central nervous system drug delivery has to cross blood brain barrier. Intranasal delivery to brain via olfactory region is best way to treat CNS diseases. Here we formulated chitosan nanoparticles by ionic gelation technique which then incorporated into the in-situ nasal gel. Poloxamer 407 at the 20% concentration is best for thermosensitive gelling mechanism. Batch F8 of nanoparticles were optimized by considering the Particle size (109.9±1.30 nm), PDI (0.363±0.013), Zeta potential (26.36±2.58 mV), %Entrapment efficiency of Levodopa (91.03±3.02) and % Entrapment efficiency of Selegiline Hydrochloride (55.01±1.97). Levodopa-selegiline hydrochloride chitosan (LDSLG- CS) nanoparticle based in-situ nasal gel was formulated by taking the batch F8 and it was found to be clear and had pH of 6.2, gelling temperature of 29 ± 0.6 0C, drug content of Levodopa in formulation was 90 ± 0.84% while of selegiline hydrochloride was found 85 ± 0.45 %. In-vitro release of LD-SLG-CS nanoparticle based in-situ nasal gel for drug Levodopa followed Higuchi kinetics and selegiline HCl followed zero order kinetics. Ex-vivo permeation study for 7 hours showed that Levodopa and selegiline HCl had 26.339 and 69.041% cumulative release respectively. In-vivo pharmacodynamic study on female wistar rats were performed; in that locomotion activity by open field test, grip strength and akinesia test had significant results which indicates that formulation had dynamic effect on the Parkinsons disease.

Keywords: Parkinson’s disease, Chitosan nanoparticles, in-situ nasal gel, Levodopa, Selegiline hydrochloride.